DEXLEVO
22.6.2022 13:23:05 CEST | Business Wire | Press release
GS, which has announced its expansion into the bio business by acquiring Hugel, a botulinum toxin manufacturer, now seeks further business expansion. The group plans to diversify its business portfolio by collaborating with technology-competitive bio ventures. Recently, it is seen to consider synergy by combining botulinum toxin and fillers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005613/en/
According to industry sources, GS’s trading arm GS Global is exploring the global filler market by signing a strategic partnership with DEXLEVO on May 20. The agreement worth 10 million dollars (KRW 12.7 billion) aims to distribute GOURI, a liquid PCL injectable of DEXLEVO in Turkey. GS is also eyeing penetrating markets in Europe and the Greater China Region.
GS focuses on DEXLEVO’s superior technology which can generate synergy with its bio portfolio. GOURI is the world’s first filler based on polycaprolactone (PCL), a biodegradable solubilized polymer. The product evenly spreads to human faces without particles after injection to form collagen.
Furthermore, the group noted the fact that filler and botulinum are complementary goods under the same aesthetic portfolio. DEXLEVO’s product GOURI received CE certification in May 2021, paving the way for exports. GS intends to export Hugel’s botulinum toxin utilizing the distribution network for DEXLEVO’s filler.
Industry officials said that Hugel had built a relationship with DEXLEVO by securing the right to exclusive distribution of DEXLEVO’s liquid polymer fillers in Korea before it was acquired by GS, and thus GS is expecting synergy when it expands the botulinum toxin business.
GS has made various moves to expand its bio business. Last year GS Global signed a business agreement with AT Sens, a developer of ECG (electrocardiogram) monitors to explore the North American market. The agreement was to sell AT-Patch, the first long-term uninterrupted ambulatory cardiac monitor launched in Korea by AT Sens to North America.
In addition, the Future Business Team of the holding company GS is exploring new businesses to seek additional sources of growth through M&A. Future business Team consists of team leader Hur Seo-Hong, and Executive Directors Gwak Won Cheol, Hwang Jae-eung, and Gu Ja-yong. The team includes more executives and most of them are looking for additional investment in biotech.
A GS group official said, "Collaboration with DEXLEVO is one of our multiple strategies to secure sources of future growth, and we will continuously explore new businesses in various areas including the bio sector."
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005613/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 08:53:00 CEST | Press release
In its largest-ever product upgrade, the company unveils an industry-first AI-native, end-to-end full financial stack with close to 100 key products across 4 business pillars.Built on newly upgraded Antom 3-in-1 Transformer, our payment foundation model, and FalconTST, our AI FX & liquidity forecast model.Underpinned by an agent-ready, 2-layered trust and security framework, and a governance-by-design approach that keeps us aligned with evolving compliance and regulatory environments.Autopilots for payment, account and treasury management embedded in the end-to-end financial stack to manage the five main workstreams in natural-language interaction.Introduces agent-native solutions including world's first Account for Agent (AFA) for businesses.89.5% of clients of our main merchant payment service already deployed our FinAI solutions in past 12 months. 81.4% of payment tasks were completed with AI help. In an industry first, Ant International launched a full stack of AI-native solutions
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 07:00:00 CEST | Press release
2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh)Commitment of USD 22.2 Million Increases Takeda’s Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health sy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom